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CASE REPORT
CASE REPORT
An 82-year-old woman presented with a palpable 
mass in the right supraclavicular fossa. Her medical history 
included coronary artery disease, for which she underwent 
percutaneous transluminal coronary angioplasty; mild aortic 
valve stenosis, and a pacemaker to treat a third-degree atrio-
ventricular block. Nine years before this clinical presentation, 
she was diagnosed with a pT4NoMo (limited disease) stage 
small-cell lung cancer (SCLC) of the left upper lobe. She was 
treated with five cycles of cyclophosphamide, doxorubicin, 
and etoposide containing chemotherapy every 3 weeks, which 
resulted in a complete response followed by prophylactic cra-
nial irradiation. She had a smoking history of 30 pack years 
but had stopped smoking 9 years earlier.
She had an Eastern Cooperative Oncology Group perfor-
mance score of 1 with normal vital signs and, apart from the palpable 
mass, no abnormalities on physical examination. Laboratory investi-
gations revealed normal blood cell counts, renal, and liver function.
A computed tomography scan of the thorax showed a 
solid lobulated leasion in the right upper lobe extending in 
the right supraclavicular fossa and mediastinal lymph node 
enlargement. Both this mass and the right upper lobelesion 
were fluorodeoxyglucose avid on positron emission tomog-
raphy-computed tomography scanning as was a small mass 
adjacent to the right adrenal gland. A biopsy was taken from 
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FIGURE 1. Hematoxylin and eosin 
stain of biopsy from first (A) and 
 second (B) SCLC are shown with 
CD56 immunohistochemical staining 
on first (C) and second (D) SCLC. 
SCLC, small-cell lung cancer.
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the supraclavicular mass and revealed SCLC (Fig. 1), staged 
as T2N3M1. The patient was treated with carboplatin-etopo-
side containing chemotherapy, resulting in a partial response. 
Shortly after the completion of five courses of chemotherapy, 
multiple brain metastases became symptomatic, for which the 
patient refused further therapy, and died within a week.
Little is known about the genetic origin of late relapses, 
and to determine whether this was a late relapse or a new pri-
mary, tissue was analyzed using high-resolution copy number 
profiling by array comparative genomic hybridization (CGH) 
(105K arrays, Agilent Technologies, Palo Alto, CA) and was 
compared with the copy number profile from DNA of the tumor 
diagnosed 9 years earlier (Fig. 2). DNA was isolated from for-
malin-fixed paraffin embedded SCLC samples, as described 
previously,1 using the commercially available QIAamp DNA 
mini kit (Qiagen, Westburg, Leusden, The Netherlands) and 
QIAamp microkit (Qiagen, Hilden, Germany). Images of the 
arrays were acquired using a micro array scanner G2505C 
(Agilent Technologies) and image analysis was performed 
using feature extraction software (version 10.1.1.1; Agilent 
Technologies). Waves not related to chromosomal copy 
number changes were smoothed, and aberrations called used 
CGHcall. Raw and processed data can be accessed using the 
Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.
gov/geo/), under accession number GSE16575. An R package 
for testing clonal relatedness of two tumors from the same 
patient based on their genomic profiles was performed and 
showed a likelihood ratio of −2.7, which indicates there is no 
relatedness between the two tumors.2
DISCUSSION
Second primary lung tumor (SPLT) in long-term sur-
vivors of SCLC is well known, and it has been stated that 
especially these patients are at very high risk of developing 
an SPLT.3–5 The problem of treating an SPLT has been more 
frequently reported in non–small-cell lung cancer (NSCLC) 
patients in whom SPLT may occur either simultaneously or 
after the treatment of the primary. Guidelines for diagnosis 
and treatment of SPLT are available for patients diagnosed 
with NSCLC.6
FIGURE 2. Chromosomal aberrations as detected by array CGH for both SCLC biopsies are shown. On the y axis is the log2 
tumor to normal ratio and on the x axis the chromosomal position in bp. Gray dots are individual array measurements (105K 
in total) and red lines, their segmented values. Gain and loss are positive and negative log2 ratio, respectively. All array data are 
available in the GEO database (GSE16575). SCLC, small-cell lung cancer.
e5Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 8, August 2012 Late Relapse or Second Primary SCLC
In SCLC patients, the SPLT is most frequently NSCLC. 
SCLC after SCLC has been found but will clinically often be 
considered as a late recurrence of the primary SCLC.7 The array 
CGH analysis demonstrates clear, distinct patterns of losses and 
gains between the two tumors that are not clonally related.
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